Skip to main content

Table 3 Base Case results (ref. Remdesivir)

From: Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study

Strategy Δ Cost Δ QALY ICER
Remdesivir ref. ref.  
Dexamethasone 1201.3 0.0295 40735.2
Rem + Dex 185.8 0.0356 5221.9